<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03575299</url>
  </required_header>
  <id_info>
    <org_study_id>GDT-MDR-TB-069</org_study_id>
    <nct_id>NCT03575299</nct_id>
  </id_info>
  <brief_title>Clinical Study on Adoptive Treatment of MDR-TB With Allogeneic γδT Cells</brief_title>
  <acronym>MDR-TB</acronym>
  <official_title>Clinical Study on Adoptive Treatment of Multidrug Resistant Pulmonary Tuberculosis With Allogeneic γδT Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhinan Yin, Ph.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shenzhen Third People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jinan University Guangzhou</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Brief summary: Allogeneic γδT cells from healthy donor will be administrated intravenously to
      patients with the MDR-TB，and then the safety and efficacy of γδT cells will be evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients with multi-drug resistant pulmonary tuberculosis will be assigned into 2
      groups(study group and control group)，both groups will receive conventional treatment.
      Allogeneic γδT cell will be administrated intravenously to patients in the study group (but
      not the control group) every two weeks for 6 months
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>sputum smear</measure>
    <time_frame>6 months</time_frame>
    <description>The sputum specimens will be collected biweekly in the first 2 months and bimonthly thereafter for sputum smear to study the time (months) of the sputum conversion. The sputum conversation rate will be analyzed at the end of study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sputum tubercle bacillus culture</measure>
    <time_frame>6 months</time_frame>
    <description>The sputum specimens will be collected for culture to detect the TB biweekly in the first 2 months and bimonthly thereafter to study the time (months) of the sputum conversion. The sputum conversation rate will be analyzed at the end of study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal microbiome analysis</measure>
    <time_frame>6 months</time_frame>
    <description>The faeces will be taken to study fecal microbiome changes biweekly in the first 2 months, and monthly thereafter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of immune function</measure>
    <time_frame>6 months</time_frame>
    <description>Peripheral blood will be collected for assessment of immune system function every time before the administration of allogeneic γδT cells .</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Multi-drug Resistant Tuberculosis</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated with anti-tuberculosis drugs, and meanwhile will be treated with Allogeneic γδT cells.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will be treated with anti-tuberculosis drugs, and meanwhile will not be treated with allogeneic γδT cells.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>The adoptive treatment of allogeneic γδT cells</intervention_name>
    <description>Allogeneic γδT cells will be administered to patients with MDR-TB every two weeks, for 12 times in a total of 6 months.</description>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>No allogeneic γδT cells will be administered to patients with MDR-TB.</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conventional treatment</intervention_name>
    <description>Patients will be treated with anti-tuberculosis drugs throughout the entire process of the study.</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Aged 18-50 years old, male or female;

          2. Informed consent;

          3. Patients with multidrug-resistant tuberculosis diagnosed by positive sputum smear and
             tubercle bacillus culture.

        Exclusion Criteria:

          1. AIDS, hepatitis B and other viruses, bacterial infections;

          2. Patients with other diseases such as diabetes, cancer, hypertension, coronary heart
             disease, endocrine system diseases, mental diseases, neurological diseases, and
             vascular circulatory diseases;

          3. Others After being evaluated by clinicians participating in this project, it is not
             suitable to participate in immune cell therapy;

          4. Those who do not agree to be included.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guofang Deng, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>Partner</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhinan Yin, Ph.D.</last_name>
    <phone>(+86)18818801179</phone>
    <email>zhinan.yin@yale.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yangzhe Wu, Ph.D.</last_name>
    <phone>(+86)18826469480</phone>
    <email>190374157@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shenzhen Third People's Hospital</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guoliang Zhang, Ph.D</last_name>
      <phone>(+86)13823317076</phone>
      <email>szdsyy@yahoo.com.cn</email>
    </contact>
    <contact_backup>
      <last_name>Guofang Deng, Master</last_name>
      <phone>(+86)13530027001</phone>
      <email>jxxk1035@yeah.net</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>June 19, 2018</study_first_submitted>
  <study_first_submitted_qc>June 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2018</study_first_posted>
  <last_update_submitted>June 29, 2018</last_update_submitted>
  <last_update_submitted_qc>June 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Jinan University Guangzhou</investigator_affiliation>
    <investigator_full_name>Zhinan Yin, Ph.D.</investigator_full_name>
    <investigator_title>Dean of Biomedical Translational Research Institute，jinan University</investigator_title>
  </responsible_party>
  <keyword>MDR-TB</keyword>
  <keyword>Allogeneic γδT cells</keyword>
  <keyword>adoptive treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Multidrug-Resistant</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

